Kenya accelerates local vaccine production with 2027 target as CS Duale visits Kenya BioVax Institute

KENYA—Health Cabinet Secretary Hon. Aden Duale has reinforced the Kenyan government’s dedication to establishing domestic vaccine manufacturing capabilities during a high-level meeting with the Board and Senior Management of the Kenya BioVax Institute.

The strategic dialogue centered on how local vaccine production will strengthen the nation’s Universal Health Coverage (UHC) initiative and enhance health security for millions of Kenyans.

The Institute operates with a clear mandate to produce and distribute safe, effective human vaccines while also developing other essential health products and technologies that support national health priorities.

During his inaugural visit to the facility, Cabinet Secretary Duale received comprehensive updates on the institute’s achievements and future plans, including the ambitious goal of releasing Kenya’s first trial batch of locally manufactured vaccines by the end of 2027.

The government has fully funded the first phase of the vaccine manufacturing facility, which has already reached completion.

Work on the second phase is now progressing, focusing on project integration and the installation of sophisticated equipment.

This phase will incorporate advanced fill-and-finish systems, which represent critical components in the vaccine production process and will enable the facility to meet international manufacturing standards.

Kenya has achieved a significant regulatory milestone by attaining World Health Organization (WHO) Maturity Level 3 status.

The Pharmacy and Poisons Board and the National Quality Control Laboratory (NQCL) provided vital support in reaching this benchmark.

This achievement establishes Kenya as a leading pharmaceutical manufacturing hub across the African continent and strengthens the country’s regulatory framework for drug production and quality control.

The Maturity Level 3 status directly supports Kenya’s UHC objectives while creating economic opportunities aligned with the 5th Administration’s Bottom-Up Economic Transformation Agenda (BETA).

This economic strategy aims to generate sustainable growth by developing key sectors that benefit ordinary citizens and create employment opportunities throughout the pharmaceutical supply chain.

Additional support for the Institute will come from the World Bank through the Regional Health Emergency Preparedness, Response, and Resilience (HEPRRP) programme.

This international partnership will boost Kenya’s pharmaceutical manufacturing capacity and strengthen the country’s ability to respond effectively to future public health emergencies, ensuring better preparedness for potential disease outbreaks or health crises.

During an interactive session with Institute staff, Cabinet Secretary Duale emphasized the constitutional principles outlined in Article 232, which mandate integrity, transparency, and accountability in public service.

He stressed that these values form the foundation for delivering people-centered healthcare that meets the needs and expectations of Kenyan citizens.

Kenya BioVax Institute Board Chairperson Dr. Charles Githinji and Chief Executive Officer Dr. Wesley Ronoh hosted the Cabinet Secretary during the visit.

Principal Secretary for Medical Services Dr. Ouma Oluga, Director-General for Health Dr. Patrick Amoth, and World Bank representative Dr. Bernard Olayo accompanied him throughout the engagement.